Abstract

Cyclooxygenase 1 and 2 (COX-1, COX-2) are enzymes that catalyze the first reaction in the arachidonic acid pathway. COXs are the therapeutic target for non-steroidal anti-inflammatory drugs. Inhibition of COX enzymatic activity has an analgesic, anti-inflammatory and sometimes antiplatelet effect. Single-nucleotide polymorphisms (SNPs) within genes encoding COX-1 and COX-2 (PTGS1, PTGS2) influence the risk of pain and their intensity in some diseases. They also affect the effectiveness of NSAID therapy in rheumatoid diseases. Moreover, the relationship between certain polymorphisms of PTGS2 and a higher risk of migraine and the development of aspirin resistance in the prophylaxis of cardiovascular diseases was demonstrated. The isoform of cytochrome P450, CYP2C9 has a significant influence on the efficacy and safety of NSAID use. It is responsible for the metabolism and speed of removal of these drugs. The occurrence of some of its polymorphic forms is associated with a decrease in CYP2C9 enzymatic activity, leading to changes in the pharmacokinetics and pharmacodynamics of NSAIDs. The prolonged half-life and decrease in clearance of these drugs lead to serious side effects such as hepatotoxicity, nephrotoxicity, anaphylactic reactions, cardiovascular or gastrointestinal incidents. Studies on polymorphisms of cyclooxygenases and CYP2C9 may improve the safety and efficacy of NSAIDs therapy by adjusting the dose to individual polymorphic variants, as well as expanding knowledge about the pathomechanism of inflammatory diseases.

References

• 1. Agúndez J.A., Blanca M., Cornejo-García J.A., García-MartínE.: Pharmacogenomics of cyclooxygenases. Pharmacogenomics,2015; 16: 501–522
  Google Scholar
• 2. Anderson B.J.: Paracetamol (acetaminophen): Mechanisms ofaction. Paediatr. Anaesth., 2008; 18: 915–921
  Google Scholar
• 3. Applebaum E., Nackley A.G., Bair E., Maixner W., Khan A.A.: Geneticvariants in cyclooxygenase-2 contribute to post-treatmentpain among endodontic patients. J. Endod., 2015; 41: 1214–1218
  Google Scholar
• 4. Ayuso P., Plaza-Serón M.D., Blanca-López N., Doña I., CampoP., Canto G., Laguna J.J., Bartra J., Soriano-Gomis V., Blanca M.,Cornejo-García J.A., Perkins J.R.: Genetic variants in arachidonicacid pathway genes associated with NSAID-exacerbated respiratorydisease. Pharmacogenomics, 2015; 16: 825–839
  Google Scholar
• 5. Beales I.: Recent advances in the management of peptic ulcerbleeding. F1000Re.s, 2017; 6: 1763
  Google Scholar
• 6. Beales I.L.: Time to reappraise the therapeutic place of celecoxib.Ther. Adv. Chronic Dis., 2018; 9: 107–110
  Google Scholar
• 7. Berinstein E., Levy A.: Recent developments and future directionsfor the use of pharmacogenomics in cardiovascular diseasetreatments. Expert Opin. Drug Metab. Toxicol., 2017; 13: 973–983
  Google Scholar
• 8. Brooks J., Warburton R., Beales I.L.: Prevention of upper gastrointestinalhaemorrhage: Current controversies and clinical guidance.Ther. Adv. Chronic Dis., 2013; 4: 206–222
  Google Scholar
• 9. Bruno A., Tacconelli S., Patrignani P.: Variability in the responseto non-steroidal anti-inflammatory drugs: Mechanisms and perspectives.Basic Clin. Pharmacol. Toxicol., 2014; 114: 56–63
  Google Scholar
• 10. Burdan F., Chałas A., Szumiło J.: Cyklooksygenaza i prostanoidy– znaczenie biologiczne. Postępy Hig. Med. Dośw., 2006; 60: 129–141
  Google Scholar
• 11. Cai H., Cai B., Sun L., Zhang H., Zhou S., Cao L., Guo H., Sun W.,Yan B., Davis S.M., Zhang Z., Liu X.: Association between PTGS1polymorphisms and functional outcomes in Chinese patients withstroke during aspirin therapy: Interaction with smoking. J. Neurol.Sci., 2017; 376: 211–215
  Google Scholar
• 12. Cairns J.A.: The coxibs and traditional nonsteroidal anti-inflammatorydrugs: A current perspective on cardiovascular risks.Canadian J. Cardiol., 2007; 23: 125–131
  Google Scholar
• 13. Cantaut-Belarif Y., Antri M., Pizzarelli R., Colasse S., Vaccari I.,Soares S., Renner M., Dallel R., Triller A., Bessis A.: Microglia controlthe glycinergic but not the GABAergic synapses via prostaglandinE2 in the spinal cord. J. Cell Biol., 2017; 216: 2979–2989
  Google Scholar
• 14. Carbo M.J., Spoorenberg A., Maas F., Brouwer E., Bos R., BootsmaH., van der Veer E., Wink F., Arends S.: Ankylosing spondylitisdisease activity score is related to NSAID use, especially in patientstreated with TNF-α inhibitors. PLoS One, 2018; 13: e0196281
  Google Scholar
• 15. Casado-Arroyo R., Bayrak F., Sarkozy A., Chierchia G.-B., de AsmundisC., Brugada P.: Role of ASA in the primary and secondaryprevention of cardiovascular events. Best Pract. Res. Clin. Gastroenterol.,2012; 26: 113–123
  Google Scholar
• 16. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., TomsikJ., Elton T.S., Simmons D.L.: COX-3, a cyclooxygenase-1 variantinhibited by acetaminophen and other analgesic/antipyreticdrugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci.USA, 2002; 99: 13926–13931
  Google Scholar
• 17. Chen L., Yang G., Grosser T.: Prostanoids and inflammatorypain. Prostaglandins Other Lipid Mediat., 2013; 104–105: 58–66
  Google Scholar
• 18. Coma-Canella I., Velasc A.: Variability in individual responsivenessto aspirin: Clinical implications and treatment. Cardiovasc.Hematol. Disord. Drug Targets, 2007; 7: 274–287
  Google Scholar
• 19. Cortes A., Maksymowych W.P., Wordsworth B.P., Inman R.D.,Danoy P., Rahman P., Stone M.A., Corr M., Gensler L.S., GladmanD., Morgan A., Marzo-Ortega H., Ward M.M., SPARCC (SpondyloarthritisResearch Consortium of Canada), TASC (Australo-Anglo-American Spondyloarthritis Consortium) i wsp.: Association studyof genes related to bone formation and resorption and the extentof radiographic change in ankylosing spondylitis. Ann. Rheum.Dis., 2015; 74: 1387–1393
  Google Scholar
• 20. Crofford L.J.: Use of NSAIDs in treating patients with arthritis.Arthritis Res. Ther., 2013; 15: S2
  Google Scholar
• 21. Dasdemir S., Cetinkaya Y., Gencer M., Ozkok E., Aydin M.,Cakmakoglu B.: Cox-2 gene variants in migraine. Gene, 2013; 518:292–295
  Google Scholar
• 22. Derry S., Moore R.A., Gaskell H., McIntyre M., Wiffen P.J.: TopicalNSAIDs for acute musculoskeletal pain in adults. Cochrane DatabaseSyst. Rev., 2015; 2015: CD007402
  Google Scholar
• 23. Derry S., Wiffen P.J., Moore R.A., McNicol E.D., Bell R.F., CarrD.B., McIntyre M., Wee B.: Oral nonsteroidal anti-inflammatorydrugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst.Rev., 2017; 2017: CD012638
  Google Scholar
• 24. Doña I., Blanca-López N., Torres M.J., García-Campos J., García-Núñez I., Gómez F., Salas M., Rondón C., Canto M.G., Blanca M.: Drughypersensitivity reactions: Response patterns, drug involved, andtemporal variations in a large series of patients. J. Investig. Allergol.Clin. Immunol., 2012; 22: 363–371
  Google Scholar
• 25. England S., Bevan S., Docherty R.J.: PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal rootganglion neurones via the cyclic AMP-protein kinase A cascade. J.Physiol., 1996; 495: 429–440
  Google Scholar
• 26. Fillingim R.B.: Individual differences in pain: Understandingthe mosaic that makes pain personal. Pain, 2017; 158: S11–S18
  Google Scholar
• 27. Fu J., Li Z., Li N.: The association between COX-2 gene rs5275polymorphism and Nasopharyngeal carcinoma risk. Pathol. Res.Pract., 2018; 214: 1579–1582
  Google Scholar
• 28. GeneCards. PTGS2 Gene(Protein Coding) Prostaglandin-EndoperoxideSynthase 2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTGS2 (03.01.2018)
  Google Scholar
• 29. Goodman T., Ferro A., Sharma P.: Pharmacogenetics of aspirinresistance: A comprehensive systematic review. Br. J. Clin. Pharmacol.,2008; 66: 222–232
  Google Scholar
• 30. Graham G.G., Scott K.F.: Mechanism of action of paracetamol.Am. J. Ther., 2005; 12: 46–55
  Google Scholar
• 31. Grosser T., Theken K.N., FitzGerald G.A.: Cyclooxygenase inhibition:Pain, inflammation, and the cardiovascular system. Clin.Pharmacol. Ther., 2017; 102: 611–622
  Google Scholar
• 32. Hahn T., Heinzel S., Plichta M.M., Reif A., Lesch K.P., FallgatterA.J.: Neurovascular coupling in the human visual cortex is modulatedby cyclooxygenase-1 (COX-1) gene variant. Cereb Cortex,2011; 21: 1659–1666
  Google Scholar
• 33. Harvey R.J., Depner U.B., Wässle H., Ahmadi S., Heindl C., ReinoldH., Smart T.G., Harvey K., Schütz B., Abo-Salem O.M., ZimmerA., Poisbeau P., Welzl H., Wolfer D.P., Betz H.: GlyR α3: An essentialtarget for spinal PGE2-mediated inflammatory pain sensitization.Science, 2004; 304: 884–887
  Google Scholar
• 34. Helmersson J., Arnlöv J., Axelsson T., Basu S.: A polymorphismin the cyclooxygenase 1 gene is associated with decreased inflammatoryprostaglandin F2α formation and lower risk of cardiovasculardisease. Prostaglandins Leukot. Essent. Fatty Acids, 2009;80: 51–56
  Google Scholar
• 35. Hingtgen C.M., Vasko M.R.: Prostacyclin enhances the evokedreleaseof substance P and calcitonin gene-related peptide fromrat sensory neurons. Brain Res., 1994; 655: 51–60
  Google Scholar
• 36. Hu H.M., Kuo C.H., Lee C.H., Wu I.C., Lee K.W., Lee J.M., GoanY.G., Chou S.H., Kao E.L., Wu M.T., Wu D.C.: Polymorphism in COX-2modifies the inverse association between Helicobacter pylori seropositivityand esophageal squamous cell carcinoma risk in Taiwan:A case control study. BMC Gastroenterol., 2009; 9: 37
  Google Scholar
• 37. Hurst E.A., Pang L.Y., Argyle D.J.: The selective cyclooxygenase- 2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effectsin vitro independent of cyclooxygenase-2 expression levels. Vet.Comp. Oncol., 2019;17: 194–207
  Google Scholar
• 38. Iskander A., Gan T.J.: Novel analgesics in ambulatory surgicalpatients. Curr. Opin. Anaesthesiol., 2018; 31: 685–692
  Google Scholar
• 39. Jaja C., Bowman L., Wells L., Patel N., Xu H., Lyon M., KutlarA.: Preemptive genotyping of CYP2C8 and CYP2C9 allelic variantsinvolved in NSAIDs metabolism for sickle cell disease pain management.Clin. Transl. Sci., 2015; 8: 272–280
  Google Scholar
• 40. Jaja C., Patel N., Scott S.A., Gibson R., Kutlar A.: CYP2C9 allelicvariants and frequencies in a pediatric sickle cell disease cohort:Implications for NSAIDs pharmacotherapy. Clin. Transl. Sci., 2014;7: 396–401
  Google Scholar
• 41. Jurado-Escobar R., Doña I., Perkins J.R., Bogas G., Pérez-sanchezN., Bartra J., Isidoro-García M., Torres Jaén M.J., Mayorga C., Cornejo-Garcia J.A.: Association of single nucleotide polymorphismsin PTGS1 and PTGS2 with aspirin-induced urticaria/angioedema.J. Allergy Clin. Immunol., 2019; 143: AB67
  Google Scholar
• 42. Kawabata A.: Prostaglandin E2 and pain – an update. Biol.Pharm. Bull., 2011; 34: 1170–1173
  Google Scholar
• 43. Khan A., Khan S., Kim Y.S.: Insight into pain modulation: Nociceptorssensitization and therapeutic targets. Curr. Drug Targets,2019; 20: 775–788
  Google Scholar
• 44. Kielbasa W., Helton D.L.: A new era for migraine: Pharmacokineticand pharmacodynamic insights into monoclonal antibodieswith a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia,2019; 39: 1284–1297
  Google Scholar
• 45. Kim S.H., Kim D.H., Byeon J.Y., Kim Y.H., Kim D.H., Lim H.J., Lee C.M., Whang S.S., Choi C.I., Bae J.W., Lee Y.J., Jang C.G., Lee S.Y.: Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch. Pharm. Res., 2017; 40: 382–390
  Google Scholar
• 46. Kirchheiner J., Meineke I., Freytag G., Meisel C., Roots I., Brockmöller J.: Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin. Pharmacol. Ther., 2002; 72: 62–75
  Google Scholar
• 47. Kirchheiner J., Störmer E., Meisel C., Steinbach N., Roots I., Brockmöller J.: Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics, 2003; 13: 473–480
  Google Scholar
• 48. Kohno T., Wang H., Amaya F., Brenner G.J., Cheng J.K., Ji R.R., Woolf C.J.: Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. J. Neurosci., 2008; 28: 4533–4540
  Google Scholar
• 49. Lee H.I., Bae J.W., Choi C.I., Lee Y.J., Byeon J.Y., Jang C.G., Lee S.Y.: Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenet. Genomics, 2014; 24: 113–117
  Google Scholar
• 50. Lee J.J., Simmons D.L.: Antipyretic therapy: Clinical pharmacology.Handb. Clin. Neurol., 2018; 157: 869–881
  Google Scholar
• 51. Lee K.H., Kim H.S., El-Sohemy A., Cornelis M.C., Uhm W.S.,Bae S.C.: Cyclooxygenase-2 genotype and rheumatoid arthritis. J.Rheumatol., 2006; 33: 1231–1234
  Google Scholar
• 52. Lee S.J., Park M.K., Shin D.S., Chun M.H.: Variability of thedrug response to nonsteroidal anti-inflammatory drugs accordingto cyclooxygenase-2 genetic polymorphism. Drug Des. Devel. Ther.,2017; 11: 2727–2736
  Google Scholar
• 53. Lee Y.S., Kim H., Wu T.X., Wang X.M., Dionne R.A.: Geneticallymediated interindividual variation in analgesic responses to cyclooxygenaseinhibitory drugs. Clin. Pharmacol. Ther., 2006; 79: 407–418
  Google Scholar
• 54. Levinson S.R., Luo S., Henry M.A.: The role of sodium channelsin chronic pain. Muscle Nerve, 2012; 46: 155–165
  Google Scholar
• 55. Li X.L., Cao J., Fan L., Wang Q., Ye L., Cui C.P., Wang Y.Z., Liu L., LiB., Wu R.J., Zhou F.C., Zhang J.H.: Genetic polymorphisms of HO-1 andCOX-1 are associated with aspirin resistance defined by light transmittanceaggregation in Chinese Han patients. Clin. Appl. Thromb.Hemost., 2013; 19: 513–521
  Google Scholar
• 56. Liu R., Gong C., Tao L., Yang W., Zheng X., Ma P., Ding L.: Influenceof genetic polymorphisms on the pharmacokinetics of celecoxib andits two main metabolites in healthy Chinese subjects. Eur. J. Pharm.Sci., 2015; 79: 13–19
  Google Scholar
• 57. Loke W.M., Sing K.L., Lee C.Y., Chong W.L., Chew S.E., Huang H.,Looi W.F., Quek A.M., Lim E.C., Seet R.C.: Cyclooxygenase-1 mediatedplatelet reactivity in young male smokers. Clin. Appl. Thromb.Hemost., 2014; 20: 371–377
  Google Scholar
• 58. Luo D., Long Y., Chen G.J.: Cyclooxygenase-2 gene polymorphismsand risk of Alzheimer’s disease: A meta-analysis. J. Neurol.Sci., 2015; 359: 100–105
  Google Scholar
• 59. Łabuz-Roszak B., Pierzchała K., Tyrpień K.: Resistance to acetylsalicylicacid in patients with type 2 diabetes mellitus is associatedwith lipid disorders and history of current smoking. J. Endocrinol.Invest., 2014; 37: 331–338
  Google Scholar
• 60. Ma W., St-Jacques B., Rudakou U., Kim Y.N.: Stimulating TRPV1externalization and synthesis in dorsal root ganglion neurons contributesto PGE2 potentiation of TRPV1 activity and nociceptor sensitization.Eur. J. Pain, 2017; 21: 575–593
  Google Scholar
• 61. Mantyh P.: Bone cancer pain: Causes, consequences, and therapeuticopportunities. Pain, 2013; 154: S54–S62
  Google Scholar
• 62. Maree A.O., Curtin R.J., Chubb A., Dolan C., Cox D., O’Brien J.,Crean P., Shields D.C., Fitzgerald D.J.: Cyclooxygenase-1 haplotypemodulates platelet response to aspirin. J. Thromb. Haemost., 2005;3: 2340–2345
  Google Scholar
• 63. Martínez C., Blanco G., Ladero J.M., García-Martín E., TaxoneraC., Gamito F.G., Diaz-Rubio M., Agúndez J.A.: Genetic predispositionto acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol.,2004; 141: 205–208
  Google Scholar
• 64. Mathivanan S., Devesa I., Changeux J.P., Ferrer-Montiel A.:Bradykinin induces TRPV1 exocytotic recruitment in peptidergicnociceptors. Front. Pharmacol., 2016; 7: 178
  Google Scholar
• 65. Moore A.E., Young L.E., Dixon D.A.: A common single-nucleotidepolymorphism in cyclooxygenase-2 disrupts microRNA-mediatedregulation. Oncogene, 2012; 31: 1592–1598
  Google Scholar
• 66. Moriyama T., Higashi T., Togashi K., Iida T., Segi E., SugimotoY., Tominaga T., Narumiya S., Tominaga M.: Sensitization of TRPV1by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins.Mol. Pain, 2005; 1: 3
  Google Scholar
• 67. Moskowitz M.A.: The neurobiology of vascular head pain. Ann.Neurol., 1984; 16: 157–168
  Google Scholar
• 68. Mozaffari E., Doosti A., Arshi A., Faghani M.: Association ofCOX-2 promoter polymorphisms –765G/C and –1195A/G with migraine.Iran J. Public Health, 2016; 45: 1625–1635
  Google Scholar
• 69. Nagao M., Sato Y., Yamauchi A.: A meta-analysis of PTGS1 andPTGS2 polymorphisms and NSAID intake on the risk of developingcancer. PLoS One, 2013; 8: e71126
  Google Scholar
• 70. Nishihara I., Minami T., Watanabe Y., Ito S., Hayaishi O.: ProstaglandinE2 stimulates glutamate release from synaptosomes ofrat spinal cord. Neurosci. Lett., 1995; 196: 57–60
  Google Scholar
• 71. Niu W., Qi Y., Wu Z., Liu Y., Zhu D., Jin W.: A meta-analysis ofreceptor for advanced glycation end products gene: Four wellevaluatedpolymorphisms with diabetes mellitus. Mol. Cell Endocrinol.,2012; 358: 9–17
  Google Scholar
• 72. Ochoa D., Prieto-Pérez R., Román M., Talegón M., Rivas A.,Galicia I., Abad-Santos F., Cabaleiro T.: Effect of gender and CYP2C9and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofenenantiomers. Pharmacogenomics, 2015; 16: 939–948
  Google Scholar
• 73. Pelletier J.P., Martel-Pelletier J., Rannou F., Cooper C.: Efficacyand safety of oral NSAIDs and analgesics in the management ofosteoarthritis: Evidence from real-life setting trials and surveys.Semin. Arthritis Rheum., 2016; 45: S22–S27
  Google Scholar
• 74. Pergolizzi J.V.,Jr. Raffa R.B., Nalamachu S., Taylor R.Jr.: Evolutionto low-dose NSAID therapy. Pain Manag., 2016; 6: 175–189
  Google Scholar
• 75. Pergolizzi J.V.Jr., Taylor R.Jr., Raffa R.B.: Intranasal ketorolac aspart of a multimodal approach to postoperative pain. Pain Pract.,2015; 15: 378–388
  Google Scholar
• 76. Pietras T., Szemraj J., Panek M., Witusik A., Banasiak M., AntczakA., Górski P.: Functional polymorphism of cyclooxygenase-2gene (G-765C) in chronic obstructive pulmonary disease patients.Mol. Biol. Rep., 2012; 39: 2163–2167
  Google Scholar
• 77. Pilotto A., Seripa D., Franceschi M., Scarcelli C., Colaizzo D.,Grandone E., Niro V., Andriulli A., Leandro G., Di Mario F., DallapiccolaB.: Genetic susceptibility to nonsteroidal anti-inflammatorydrug-related gastroduodenal bleeding: Role of cytochrome P4502C9 polymorphisms. Gastroenterology, 2007; 133: 465–471
  Google Scholar
• 78. Pinho-Ribeiro F.A., Verri W.A.Jr., Chiu I.M.: Nociceptor sensoryneuron-immune interactions in pain and inflammation. TrendsImmunol., 2017; 38: 5–19
  Google Scholar
• 79. Prieto-Pérez R., Ochoa D., Cabaleiro T., Román M., Sánchez-Rojas S.D., Talegón M., Abad-Santos F.: Evaluation of the relationshipbetween polymorphisms in CYP2C8 and CYP2C9 and the pharmacokineticsof celecoxib. J. Clin. Pharmacol., 2013; 53: 1261–1267
  Google Scholar
• 80. Qandil A.M.: Prodrugs of nonsteroidal anti-inflammatory drugs(NSAIDs), more than meets the eye: A critical review. Int. J. Mol.Sci., 2012; 13: 17244–17274
  Google Scholar
• 81. Rodrigues A.D.: Integrated cytochrome P450 reaction phenotyping:Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem.Pharmacol., 1999; 57: 465–480
  Google Scholar
• 82. Sachs D., Villarreal C.F., Cunha F.Q., Parada C.A., Ferreira S.H.:The role of PKA and PKCε pathways in prostaglandin E2-mediatedhypernociception. Br. J. Pharmacol., 2009; 156: 826–834
  Google Scholar
• 83. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A.,Poole S., Bonventre J.V., Woolf C.J.: Interleukin-1β-mediated inductionof Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.Nature, 2001; 410: 471–475
  Google Scholar
• 84. Sandor P.S., Gantenbein A.R.: Migräneprophylaxe 2019 – dieRolle der CGRP Antagonisten. Ther. Umsch., 2018; 75: 455–457
  Google Scholar
• 85. Schuh C.D., Brenneis C., Zhang D.D., Angioni C., SchreiberY., Ferreiros-Bouzas N., Pierre S., Henke M., Linke B., Nüsing R.,Scholich K., Geisslinger G.: Prostacyclin regulates spinal nociceptiveprocessing through cyclic adenosine monophosphate-inducedtranslocation of glutamate receptors. Anesthesiology, 2014; 120:447–458
  Google Scholar
• 86. Sneader W.: The discovery of aspirin: A reappraisal. BMJ, 2000;321: 1591–1594
  Google Scholar
• 87. SNPedia. rs1057910. https://www.snpedia.com/index.php/Rs1057910 (28.08.2018)
  Google Scholar
• 88. SNPedia. rs1799853. https://www.snpedia.com/index.php/Rs1799853 (14.09.2018)
  Google Scholar
• 89. Theken K.N.: Variability in analgesic response to non-steroidalanti-inflammatory drugs. Prostaglandins Other Lipid Mediat,2018; 139: 63–70
  Google Scholar
• 90. Theken K.N., Hersh E.V., Lahens N.F., Lee H.M., Li X., GranquistE.J., Giannakopoulos H.E., Levin L.M., Secreto S.A., Grant G.R.,Detre J.A., FitzGerald G.A., Grosser T., Farrar J.T.: Variability inthe analgesic response to ibuprofen is associated with cyclooxygenaseactivation in inflammatory pain. Clin. Pharmacol. Ther.,2019; 106: 632–641
  Google Scholar
• 91. van Booven D., Marsh S., McLeod H., Carrillo M.W., SangkuhlK., Klein T.E., Altman R.B.: Cytochrome P450 2C9-CYP2C9. Pharmacogenet.Genomics, 2010; 20: 277-281
  Google Scholar
• 92. Vardeh D., Mannion R.J., Woolf C.J.: Toward a mechanism-basedapproach to pain diagnosis. J. Pain, 2016; 17: T50–T69
  Google Scholar
• 93. Vardeh D., Wang D., Costigan M., Lazarus M., Saper C.B., WoolfC.J., FitzGerald G.A., Samad T.A.: COX2 in CNS neural cells mediatesmechanical inflammatory pain hypersensitivity in mice. J. Clin.Invest., 2009; 119: 287–294
  Google Scholar
• 94. Wang C., Gu Y., Li G.W., Huang L.Y.: A critical role of the cAMPsensor Epac in switching protein kinase signalling in prostaglandinE2-induced potentiation of P2X3 receptor currents in inflamedrats. J. Physiol., 2007; 584: 191–203
  Google Scholar
• 95. Wang H., Ehnert C., Brenner G.J., Woolf C.J.: Bradykinin andperipheral sensitization. Biol. Chem., 2006; 387: 11–14
  Google Scholar
• 96. Wang H., Sun L., Jiang M., Liu L., Wang G.: -1195 A/G promotervariants of the cyclooxygenase-2 gene increases the risk of painoccurrence in endometriotic women. Clin. Exp. Obstet Gynecol.,2016; 43: 254–257
  Google Scholar
• 97. Wang L., Bao S.H., Pan P.P., Xia M.M., Chen M.C., Liang B.Q.,Dai D.P., Cai J.P., Hu G.X. .: Effect of CYP2C9 genetic polymorphismon the metabolism of flurbiprofen in vitro. Drug Dev. Ind. Pharm.,2015; 41: 1363–1367
  Google Scholar
• 98. Wang Y., Yi X.D., Lu H.L.: Influence of CYP2C9 and COX-2 geneticpolymorphisms on clinical efficacy of non-steroidal antiinflammatorydrugs in treatment of ankylosing spondylitis. Med.Sci. Monit., 2017; 23: 1775–1782
  Google Scholar
• 99. Weng Z., Li X., Li Y., Lin J., Peng F., Niu W.: The association offour common polymorphisms from four candidate genes (COX-1,COX-2, ITGA2B, ITGA2) with aspirin insensitivity: A meta-analysis.PLoS One, 2013; 8: e78093
  Google Scholar
• 100. Xu Z.H., Jiao J.R., Yang R., Luo B.Y., Wang X.F., Wu F.: Aspirinresistance: Clinical significance and genetic polymorphism. J. Int.Med. Res., 2012; 40: 282–292
  Google Scholar
• 101. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A.,Worley P.F.: Expression of a mitogen-inducible cyclooxygenase inbrain neurons: Regulation by synaptic activity and glucocorticoids.Neuron, 1993; 11: 371–386
  Google Scholar
• 102. Yang J., Chen X., Zhou J., Hu S., Tang Y.: Associations of candidategene polymorphisms with poor responsiveness to aspirin: Ameta-analysis. Clin. Exp. Pharmacol. Physiol., 2018; 46: 404
  Google Scholar
• 103. Zgorzalewicz M.: Patomechanizm migrenowych bólów głowy.Neurol. Dziec., 2005; 14: 7–14
  Google Scholar
• 104. Zhang M., Yang Y., Zhao G., Di X., Xu L., Jiang N., Xu J., Xu X.:Effect of CYP2C9 3 mutant variants on meloxicam pharmacokineticsin a healthy Chinese population. Genet. Mol. Res., 2014;13: 831–837
  Google Scholar
• 105. Zhou Y., Boudreau D.M., Freedman A.N.: Trends in the use ofaspirin and nonsteroidal anti-inflammatory drugs in the generalU.S. population. Pharmacoepidemiol. Drug Saf., 2014; 23: 43–50
  Google Scholar

Full text